Results 211 to 220 of about 101,286 (277)

Adjuvant nivolumab after chemoradiotherapy and resection for patients with esophageal cancer: A real‐world matched comparison of overall survival

International Journal of Cancer, Volume 158, Issue 5, Page 1292-1301, 1 March 2026.
What's New? Patients with esophageal or gastroesophageal junction (GEJ) cancer with residual disease after treatment with neoadjuvant chemoradiotherapy (nCRT) and resection frequently experience poor survival. Improvements in outcome, however, may be possible using adjuvant treatment with nivolumab.
Rob H. A. Verhoeven, Steven C. Kuijper, Marije Slingerland, Bas Wijnhoven, Mark I. van Berge Henegouwen, Peter S. N. van Rossum, Sarah Derks, Bianca Mostert, Nadia Haj Mohammad, Hanneke W. M. van Laarhoven   +9 more
wiley   +1 more source

Immune-Related Esophagitis and Durable Response to Second-Line Treatment With Nivolumab in Stage IV Squamous Cell Esophageal Carcinoma. [PDF]

Cureus
Meneses O, Alzamora M, Dias C, Ortigão R, Marques D.   +4 more
europepmc   +1 more source

Anti‐Melanoma Differentiation‐Associated Gene 5 Antibody‐Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Anti‐melanoma differentiation‐associated gene 5 antibody‐positive interstitial lung disease is a rare but fatal adverse event following immune checkpoint inhibitor treatment for cancers. However, such cases have not been previously reported in patients with urothelial carcinoma.
Akira Saito, Hiroki Ishihara, Hanae Kondo, Toshio Takagi, Yasunobu Hashimoto   +4 more
wiley   +1 more source

Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal.

Health Technol Assess
Lee D, Muthukumar M, Lovell A, Farmer C, Burns D, Matthews J, Coelho H, O'Toole B, Trigg LA, Snowsill TM, Barnish MS, Nikoglou T, Brand A, Ahmad Z, Abdelsabour A, Crathorne L, Robinson S, Wilson EC, Melendez-Torres GJ.   +18 more
europepmc   +1 more source

Oral Malignant Melanoma Achieving Long-Term Survival With Nivolumab Monotherapy Following Surgical Treatment: A Report of a Rare Case. [PDF]

Cureus
Kobayashi S, Todoroki K, Matsuo K, Abe Y, Kusukawa J.   +4 more
europepmc   +1 more source

Checkpoint Inhibitors and Beyond: A Systematic Review of Immunotherapy in Cutaneous Malignancies. [PDF]

Cureus
Rashid Y, Devi S K, Gonzalez-Espinosa TF, Jain J, Dalain M, Baig R, D'Amico GA, Mowo-Wale AG, Khomchenko M, Baby N, Yateem D, Duhamel A, Ali R.   +12 more
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1250-1270, March 2026.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Exceptional response to chemo-immunotherapy in a patient with HER2-negative, TMB-high metastatic gastric mucinous adenocarcinoma: a case report and literature review. [PDF]

Front Immunol
Liu C, Li X, Qi Q, Jing F, Lv J, Qiu W, Wang S.   +6 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source